Generalized Anxiety Disorder (GAD) Clinical Trials

Find Generalized Anxiety Disorder (GAD) Clinical Trials Near You

A Randomized Rater-Blinded Trial Comparing Continuous Theta Burst Stimulation Targeting the Right Posterior Parietal Cortex and Right Dorsolateral Prefrontal Cortex for Generalized Anxiety Disorder

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This randomized, rater-blinded clinical trial evaluates the effectiveness, safety, and tolerability of continuous theta burst stimulation (cTBS) in adults with generalized anxiety disorder (GAD). Participants will be randomly assigned in a 1:1 ratio to receive cTBS targeting either the right posterior parietal cortex (R-PPC) or the right dorsolateral prefrontal cortex (R-DLPFC). Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria. The primary objective is to compare changes in anxiety symptom severity, measured using the Hamilton Anxiety Rating Scale (HAM-A), from baseline to the end-of-treatment assessment. Secondary and exploratory assessments include treatment response and remission, quality of life, sleep quality, cognitive function, safety and tolerability, resting electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Age 18 to 65 years.

• Right-handed.

• Diagnosis of generalized anxiety disorder (GAD) according to ICD-10 criteria (F41.1), confirmed by a psychiatrist.

• GAD must be the primary diagnosis and the main reason for treatment at the time of enrollment. Current or past comorbid major depressive disorder will be identified and recorded.

• Hamilton Anxiety Rating Scale (HAM-A) total score \>18 at screening/baseline.

• Able and willing to provide written informed consent and comply with essential study procedures.

• Participants may be psychotropic-medication naïve or may be receiving psychotropic medication. Participants currently receiving psychotropic medication must have maintained the same medication(s) and dose(s) for at least 2 weeks before randomization; for fluoxetine, the required stable period is at least 4 weeks.

Locations
Other Locations
Viet Nam
Military Hospital 175
RECRUITING
Ho Chi Minh City
Contact Information
Primary
Dang Minh Ly, MD
drminhdang@outlook.com
+84359999741
Time Frame
Start Date: 2026-09-09
Estimated Completion Date: 2028-06
Participants
Target number of participants: 40
Treatments
Experimental: cTBS Right Posterior Parietal Cortex
Participants receive continuous theta burst stimulation (cTBS) targeting the right posterior parietal cortex (R-PPC). Treatment is delivered at 80% of the resting motor threshold (RMT), with 600 pulses per session. Participants receive two sessions per treatment day, separated by 30 ± 5-minute intervals, for a total of 10 sessions over approximately 1 week. Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria.
Experimental: cTBS Right Dorsolateral Prefrontal Cortex
Participants receive continuous theta burst stimulation (cTBS) targeting the right dorsolateral prefrontal cortex (R-DLPFC). Treatment is delivered at 100% of the resting motor threshold (RMT), with 600 pulses per session. Participants receive one session per treatment day, 5 days per week for 4 weeks, for a total of 20 sessions. Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria.
Related Therapeutic Areas
Sponsors
Leads: Military Hospital 175

This content was sourced from clinicaltrials.gov

Similar Clinical Trials